Share Facebook Twitter LinkedIn Pinterest Email Zenas BioPharma Prices $300M Capital Raise in Dual Offering
Netskope projects 24% FY2027 revenue growth and raises outlook while CFO Del Matto plans retirement (NASDAQ:NTSK)June 4, 2026